

1 **COVID-19 cases from the first local outbreak of SARS-CoV-2 B.1.1.7 variant in**
2 **China presented more serious clinical features: a prospective, comparative cohort**
3 **study**

4
5 Yang Song^{2*}, Ziruo Ge^{1*}, Shuping Cui^{1, 3*}, Di Tian¹, Gang Wan¹, Shuangli Zhu²,
6 Xianbo Wang¹, Yu Wang¹, Xiang Zhao², Pan Xiang¹, Yanli Xu¹, Tingyu Zhang¹, Long
7 Liu¹, Gang Liu¹, Yanhai Wang², Jianbo Tan¹, Wei Zhang^{1#}, Wenbo Xu^{2#}, and Zhihai
8 Chen^{1#}

9
10 ¹Emergency department of COVID-19, Beijing Ditan Hospital, Capital Medical
11 University, Beijing, China.

12 ²National Institute for Viral Disease Control and Prevention, Chinese Center for
13 Disease Control and Prevention, Beijing, China.

14 ³Peking University, Ditan Teaching Hospital, Beijing, China.

15
16
17 *Yang Song, Ziruo Ge, and Shuping Cui contributed equally to this paper.

18 #Co-corresponding authors: Zhihai Chen, E-mail: chenzhihai0001@126.com; Wenbo
19 Xu, E-mail: xuwb@ivdc.chinacdc.cn; Wei Zhang, E-mail: snowpine12@sina.com

20
21
22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Summary**

24 **Background:** The SARS-CoV-2 B.1.1.7 variant which was first identified in the United
25 Kingdom (U.K.) has increased sharply in numbers worldwide and was reported to be
26 more contagious. On January 17, 2021, a COVID-19 clustered outbreak caused by
27 B.1.1.7 variant occurred in a community in Daxing District, Beijing, China. Three
28 weeks prior, another non-variant (lineage B.1.470) COVID-19 outbreak occurred in
29 Shunyi District, Beijing. This study aimed to investigate the clinical features of B.1.1.7
30 variant infection.

31 **Methods:** A prospective cohort study was conducted on COVID-19 cases admitted to
32 Ditan hospital since January 2020. Data of 74 COVID-19 cases from two independent
33 COVID-19 outbreaks in Beijing were extracted as study subjects from a Cloud Database
34 established in Ditan hospital, which included 41 Shunyi cases (Shunyi B.1.470 group)
35 and 33 Daxing cases (Daxing B.1.1.7 group) that have been hospitalized since
36 December 25, 2020 and January 17, 2021, respectively. We conducted a comparison of
37 the clinical characteristics, RT-qPCR results and genomic features between the two
38 groups.

39 **Findings:** Cases from Daxing B.1.1.7 group (15 [45.5%] male; median age, 39 years
40 [range, 30.5, 62.5]) and cases from Shunyi B.1.470 group (25 [61.0%] male; median
41 age, 31 years [range, 27.5, 41.0]) had a statistically significant difference in median age
42 ($P=0.014$). Seven clinical indicators of Daxing B.1.1.7 group were significantly higher
43 than Shunyi B.1.470 group including patients having fever over 38°C (14/33 [46.43%]
44 in Daxing B.1.1.7 group vs. 9/41 (21.95%) in Shunyi B.1.470 group [$P=0.015$]), C-

45 reactive protein ([CRP, mg/L], 4.30 [2.45, 12.1] vs. 1.80, [0.85, 4.95], [P = 0.005]),
46 Serum amyloid A ([SAA, mg/L], 21.50 [12.50, 50.70] vs. 12.00 [5.20, 26.95], [P =
47 0.003]), Creatine Kinase ([CK, U/L]), 110.50 [53.15,152.40] vs. 70.40 [54.35,103.05],
48 [P = 0.040]), D-dimer ([DD, mg/L], 0.31 [0.20, 0.48] vs. 0.24 [0.17,0.31], [P = 0.038]),
49 CD4⁺ T lymphocyte ([CD4⁺ T, mg/L], [P = 0.003]) , and Ground-glass opacity (GGO)
50 in lung (15/33 [45.45%] vs. 5/41 [12.20%], [P =0.001]). After adjusting for the age
51 factor, B.1.1.7 variant infection was the risk factor for CRP (P = 0.045, Odds ratio [OR]
52 2.791, CI [1.025, 0.8610]), SAA (0.011, 5.031, [1.459, 17.354]), CK (0.034, 4.34, [0.05,
53 0.91]), CD4⁺ T (0.029, 3.31, [1.13, 9.71]), and GGO (0.005, 5.418, [1.656, 17.729]) of
54 patients. The median Ct value of RT-qPCR tests of the N-gene target in the Daxing
55 B.1.1.7 group was significantly lower than the Shunyi B.1.470 group (P=0.036). The
56 phylogenetic analysis showed that only 2 amino acid mutations in spike protein were
57 detected in B.1.470 strains while B.1.1.7 strains had 3 deletions and 7 mutations.

58 **Interpretation:** Clinical features including a more serious inflammatory response,
59 pneumonia and a possible higher viral load were detected in the cases infected with
60 B.1.1.7 SARS-CoV-2 variant. It could therefore be inferred that the B.1.1.7 variant may
61 have increased pathogenicity.

62 **Funding:** The study was funded by the National Key Research and Development
63 Program (grant nos.2020YFC0846200 and 2020YFC0848300) and National Natural
64 Science Foundation of China (grant no. 82072295).

65

66 **Keywords:** COVID-19; SARS-CoV-2; B.1.1.7 Variant; clinical features; RT-qPCR test;

67 whole-genomic analysis

68

69 INTRODUCTION

70 Since December 2019, the coronavirus disease-19 (COVID-19) pandemic caused by the

71 highly infectious virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

72 has been rapidly spreading, which has posed a great threat to global public health^{1,2}.

73 With the continuous transmission and mutation of SARS-CoV-2, some viral variants of

74 concern (VOC) and viriants of interest (VOI) have been reported in recent months³⁻⁸.

75 On December 14, 2020, the United Kingdom reported a SARS-CoV-2 variant of

76 concern (VOC) that belonged to the PANGO lineage B.1.1.7^{9,10}, referred to as "SARS-

77 CoV-2 VOC-202012/01", "B.1.1.7", 501Y.V1 or 20I/501Y.V1 (the term B.1.1.7 was

78 used in the whole text). The B.1.1.7 variant was estimated to have emerged in late

79 September 2020 and has increased sharply to become the predominant SARS-CoV-2

80 strain in England, which has soon become a global concern^{7,11,12}.

81

82 With the strict prevention and control policies implemented in China, local epidemics

83 have rarely occurred in Beijing. Occasionally, a small clustered outbreak triggered by

84 an imported SARS-CoV-2 strain with only one chain of transmission could happen. On

85 January 17, 2021, a clustered COVID-19 outbreak in community had taken place in

86 Daxing District, Beijing. Confirmed by whole-genome sequencing and lineage typing

87 results^{9,10}, this outbreak was caused by SARS-CoV-2 B.1.1.7 variants. This is the first

88 local transmission of B.1.1.7 variants in China, which constituted a new challenge to

89 the prevention and control of COVID-19 in China. Meanwhile, three weeks prior to the

90 Daxing outbreak, there was another local COVID-19 outbreak occurring in Shunyi
91 district in Beijing, caused by the B.1.470 lineage which was mostly detected in Asian
92 countries, both outbreaks had been well-controlled within a month.

93

94 Since the early transmission of COVID-19 in January, 2020, a cohort of COVID-19
95 cases have been established in Beijing Ditan hospital; and since June, 2020, the COVID-
96 19 cases in Beijing have only been admitted to Ditan hospital, following which a cloud
97 database had been established and maintained by Ditan hospital cooperating with a
98 Beijing technology company (Beijing Zechuang Tiancheng Technology Development
99 Co., Ltd). All relevant data for COVID-19 cases are constantly being entered into the
100 cloud database for preparing for future prospective studies. So far, the data of about 690
101 cases were completely inputted. In this study, groups of two recent independent
102 clustered outbreaks caused by distinct lineage strains and occurring in different districts
103 in Beijing (Daxing B.1.1.7 group and Shunyi B.1.470 group) were selected as the study
104 subjects from the cloud database. The COVID-19 cases from the two groups received
105 alike clinical tests and treatments and each case was observed for at least 28 days. The
106 discharge criteria included disappearance or marked improvement of clinical symptoms
107 combined with two real-time reverse transcription quantitative PCR (RT-qPCR) tests
108 negative on nasopharyngeal swabs more than 24 hours apart, based on *Diagnosis and*
109 *Treatment Protocol for Novel Coronavirus Pneumonia Patients (Version 8)*.

110

111 Recent studies indicated that the B.1.1.7 variant has a 50% higher transmissibility¹³.

112 Fortunately, some immunological and serological studies indicated that the B.1.1.7
113 variant does not escape vaccine protection^{14,15}. The UK government and related
114 scientists suggested the B.1.1.7 variant may be more deadly, but currently there is no
115 published biological experimental evidence regarding the virulence or pathogenicity of
116 B.1.1.7¹⁶.

117

118 This study is aiming at comparing the clinical presentations, the RT-qPCR results and
119 the whole-genomic features of cases from Daxing B.1.1.7 group and Shunyi B.1.470
120 group, in order to evaluate the COVID-19 severity of the cases infected by the B.1.1.7
121 variant.

122

123 **METHODS**

124 **Study design and recruitment of cases**

125 This prospective cohort study were reported according to the STROBE statement and
126 included two groups with a total of 74 confirmed COVID-19 cases from Beijing Ditan
127 Hospital, Daxing B.1.1.7 group and Shunyi B.1.470 group, based on the different
128 Districts and genomic typing results. The data of all the cases from the two groups were
129 extracted from the cloud database. The confirmed cases referred to patients with clinical
130 features of COVID-19 and positive RT-qPCR test for SARS-CoV-2 RNA at least once
131 on the respiratory specimens collected. The Daxing B.1.1.7 group contained a total of
132 33 cases whereas Shunyi B.1.470 group contained 41 cases. COVID-19 patients were
133 diagnosed according to the 8th version of *Diagnosis and Treatment Protocol for Novel*

134 *Coronavirus Pneumonia Patients*, and the clinical severity was categorized into 4 grades:
135 mild (the clinical symptoms were mild, and there was no sign of pneumonia on imaging),
136 moderate (showing fever and respiratory symptoms, imaging manifestations of
137 pneumonia), severe (1. dyspnea with a respiratory rate $>30/\text{min}$; 2. hypoxemia with
138 oxygen saturation $<93\%$; 3. $\text{PaO}_2/\text{FiO}_2 <300 \text{ mmHg}$; 4. or the clinical symptoms
139 worsened gradually, and the lung imaging showed that the lesions progressed more than
140 50% within 24-48 hours) and critical (developed complications including 1. respiratory
141 failure that needs mechanical ventilation; 2. shock; 3. patients with other organ failure
142 need ICU monitoring treatment). The asymptomatic cases with no clinical symptoms
143 but positive for RT-qPCR were also required to be admitted to the hospital. Ditan
144 Hospital is affiliated with Capital Medical University, an academic tertiary care center
145 in Beijing, China. The hospital is also a designated center in Beijing for the diagnosis
146 and treatment of COVID-19. Each case was observed for at least 28 days. As of this
147 study, four cases from Daxing outbreak and one case from Shunyi outbreak were still
148 hospitalized.

149

150 The index case of the Shunyi B.1.470 group was an asymptomatic case confirmed on
151 December 23, 2020. He intended to leave Beijing for taking an exam, so he took the
152 initiative to conduct nucleic acid detection before leaving in accordance with the
153 regulations. Further epidemiological investigation indicated that he was infected by an
154 salesperson of a mall, and the salesperson was infected by an foreign personnel who
155 was an imported asymptomatic case that had tested negative for SARS-CoV-2 RNA

156 within 14 days of entry. This was a clustered outbreak occurred mainly in workplaces
157 in Shunyi District, with the majority of cases being young people. In addition, a family
158 clustered infection including 7 members was detected.

159

160 The discovery of the index case of the Daxing B.1.1.7 group came from the routine
161 screening of SARS-CoV-2 nucleic acid detection of a resident who intended to return
162 home. The epidemiological investigation and nucleic acid detection of his close contacts
163 indicated that a clustered outbreak had already occurred in the community where the
164 case resided, of which most cases were elderly and children. Family clustered infection
165 was mostly seen, involving a total of 13 families, of which 5 families were infected with
166 more than 3 members and several families were infected with all members.

167

168 **Data collection**

169 The data of the 74 COVID-19 cases from the two groups were extracted from the cloud
170 database. Medical record review was performed to collect patients' underlying medical
171 conditions and symptoms at the time of diagnosis, including data of chronology of
172 symptom onset, history of first presentation, disease progression, past medical history,
173 physical findings, laboratory test results, imaging results, treatment and hospital course.
174 In addition, epidemiological data of the patients were collected. Individual data were
175 compiled into two groups of patients with the Daxing B.1.1.7 group and the Shunyi
176 B.1.470 group for further analyses.

177

178 **Laboratory Testing**

179 The oropharyngeal swab, nasopharyngeal swab, or sputum specimens obtained from
180 patients during their hospital stays were collected for RT-qPCR testing. Viral RNA was
181 extracted directly from 200- μ L swab samples with a QIAamp Viral RNA Mini Kit
182 (QIAGEN, Germany). RT-qPCR was conducted using a commercial Novel SARS-CoV-
183 2 Nucleic Acid Test Kit (BioGerm, Shanghai, China) with a fluorescence PCR detector
184 following the manufacturers' instructions. A TaqMan probe-based kit was designed to
185 detect the ORF1ab and N genes of SARS-CoV-2 in 1 reaction. Corresponding serum
186 samples were tested for anti-SARS-CoV-2 antibodies using a chemiluminescence
187 immunoassay (CLIA, Bioscience, Qingchong, China).

188

189 **Whole-genome sequencing and analysis**

190 The selected swab samples of the patients were then sent to China CDC for further
191 whole-genome sequencing. Libraries were prepared using a Nextera XT Library Prep
192 Kit (Illumina, San Diego, CA, USA), and the resulting DNA libraries were sequenced
193 on either a MiSeq or an iSeq platform (Illumina) using a 300-cycle reagent kit. Mapped
194 assemblies were generated using the SARS-CoV-2 genome (accession number
195 NC_045512) as a reference. Variant calling, genome alignment, and sequence
196 illustrations were generated with CLCBio software. The whole-genome sequence
197 alignment was conducted using the Muscle tool in MEGA (v7.0). Neighbor-joining
198 phylogenetic tree was constructed using the Kimura 2-parameter model with 1,000
199 bootstrap replicates. Genomic lineage designation was used "PANGO lineage" typing
200 method (<https://cov-lineages.org/>).

201

202 **Statistical analysis**

203 The statistical analyses were performed using SPSS Version 24.0 (SPSS IBM, Armonk,
204 NY, USA). We compiled data from each individual patient for the demography and
205 clinical variables. Normal continuous variables were represented by mean and std, T-
206 test was used to compare the statistical difference. Non-normal continuous variables
207 were represented by median and quartile ranges, Mann-Whitney U test was used.
208 Categorical variables were expressed as numbers and percentages, Chi-squared and
209 Fisher's exact tests were used to compare the statistical difference. Binary logistic
210 regression analysis was performed to analyze the risk factors for the severity of COVID-
211 19. All tests were two-tailed, and statistical significance was defined as P value lower
212 than 0.05.

213

214 **Role of the funding source**

215 The study was funded by the National Key Research and Development Program (grant
216 nos. 2020YFC0846200 and 2020YFC0848300) and National Natural Science
217 Foundation of China (grant no. 82072295). The funding body was not involved in the
218 study design, clinical sample collection, data analysis, and interpretation or writing of
219 the manuscript.

220 .

221 **RESULTS**

222 **Whole genome sequencing and analysis of the SARS-CoV-2 samples in the two**

223 **outbreaks**

224 Clinical samples from 8 patients of the Daxing outbreak, 13 patients of the Shunyi
225 Outbreak were sent to the China CDC for further sequencing. Some samples may be
226 degraded due to transportation or storage. Finally, a total of 9 whole-genome sequences
227 with good quality and coverage were obtained, including 7 from the Daxing outbreak
228 and 2 from the Shunyi outbreak. Compared with the Wuhan reference sequence
229 (EPI_ISL_402119), seven Daxing strains shared 31 nucleotide substitutions, six strains
230 were identical, one had an addition substitution (32 substitutions) (Table 1). These seven
231 strains shared all 28 nucleotide mutations that were first detected in the B.1.1.7 variant
232 from the UK (Figure 2). Likewise, they had 3 amino acid deletions and 7 amino acid
233 mutations on the spike protein corresponding to the characteristics of B.1.1.7 variants.

234

235 The two strains of the Shunyi outbreak shared 24 nucleotide substitutions and one of
236 them had an additional substitution (Table 1), which contained the single nucleotide
237 polymorphisms (SNPs) defining PANGO lineage B.1.470 confirmed by Pangolin
238 COVID-19 Lineage Assigner Web application^{9,10} (<https://pangolin.cog-uk.io/>). This
239 lineage is composed of only a hundred more sequences on the GISAID database, most
240 of which (77.0%) were from Indonesia. Strains from the GISAID database¹⁷ which had
241 high homology with these 2 strains were retrieved, including a Singaporean and an
242 Indonesian strain that shared 21 and 20 nucleotide substitutions with the Shunyi strains,
243 respectively (Figure 1).

244

245 **Comparison of the general information and basic clinical manifestations in the two**
246 **groups**

247 Of the 33 cases from the Daxing B.1.1.7 group and 41 from the Shunyi B.1.470 group
248 (table1), male cases accounted for 45.50% and 61.00%, respectively. The median age
249 of the two groups (39 years [interquartile range [IQR]30.50-62.50], vs. 31 years [IQR
250 27.50-41.00]) showed a statistically significant difference ($P = 0.014$). Moderate cases
251 took up the highest percentage of both groups (66.67% vs. 48.78%). The most common
252 symptoms in both groups were fever, followed by dry cough and dry throat/pharyngeal
253 discomfort. Of patients infected with B.1.1.7 variant, 14 (46.43%) had fever over 38°C,
254 significantly higher than 9 (21.95%) observed in patients infected with B.1.470 non-
255 variant ($P = 0.015$).

256
257 **Comparison of laboratory tests, imageological diagnosis and treatment measures**

258 There were no significant differences in the levels of white blood cells, neutrophils,
259 lymphocytes, platelets, Alanine and Aspartate aminotransferases in the two groups
260 (Table 2). However, the level of C-reactive protein (CRP), serum amyloid A(SAA),
261 creatine kinase (CK), and D-dimer (DD) in the Daxing B.1.1.7 group was significantly
262 higher than the Shunyi B.1.470 group ($P = 0.005, 0.003, 0.040$ and 0.038 , respectively).
263 In addition, except for 1 case in the Daxing B.1.1.7 group and 2 cases in the Shunyi
264 B.1.470 group who did not tested for T lymphocyte due to their young age, the abnormal
265 proportion of $CD4^+$ T lymphocytes($CD4^+T$) in the Daxing B.1.1.7 group was
266 significantly higher than the Shunyi B.1.470 group ($P = 0.003$). For the imageological

267 diagnosis, there were no significant differences in the incidence of pneumonia, but the
268 Ground-glass opacity (GGO) observed in the B.1.1.7-variant patients was significantly
269 higher ($P = 0.001$). The antibody detection results and clinical treatments were not
270 statistically different in the two groups.

271

272 **B.1.1.7 variant infection was the main risk for more serious COVID-19 clinical** 273 **features**

274 In order to avoid the influence of older age in the Daxing B.1.1.7 group, binary logistic
275 regression analysis was further performed for investigating the level of CRP (< 7 mg/L
276 or ≥ 7 mg/L), SAA (< 10 mg/L or ≥ 10 mg/L), CK (< 150 U/L or ≥ 150 U/L), DD ($<$
277 0.5 mg/L or ≥ 0.5 mg/L), CD4⁺ T (< 706 mg/L or ≥ 706 mg/L) and GGO in the lung
278 (Table 3). After adjusting for age factor, we found that the group factor (B.1.1.7 variant
279 infection or non-variant infection) was the main risk for CRP (Odds ratio [OR] = 2.79,
280 $P = 0.045$), SAA (OR = 5.03, $P = 0.011$), CK (OR = 0.22, $P = 0.034$), GGO (OR = 5.42,
281 $P = 0.005$), and CD4⁺ T (OR = 3.31, $P = 0.029$) of patients.

282

283 **Comparison of RT-qPCR threshold-crossing (Ct) values between the two groups**

284 During the hospitalization of all the cases, several RT-qPCR tests using nasopharyngeal
285 swabs were regularly conducted based on their disease progression and clinical
286 manifestations. The lowest Ct value of ORF1ab and N gene of each case was selected
287 and compared between the two groups (Table 4). The Kits for RT-qPCR testing had
288 uniform lot number and the instrument was the same. The median Ct value of ORF1ab-

289 gene target in the two groups had no statistically significant difference, but that of N-
290 gene target was significantly lower for the Daxing B.1.1.7 group than the Shunyi
291 B.1.470 group ($t=2.139$, $P=0.036$). The distribution of the samples in the two groups
292 was compared within all ORF1ab and N-gene Ct values (Figure 1). Figure 1b indicates
293 that in N-gene, the median Ct values of the Daxing B.1.1.7 group were lower. In addition,
294 we also adjusted the age factor and performed binary logistic regression analysis for the
295 level of Ct values (>18 or ≤ 18) (Table 5). Similarly, patients infected with the B.1.1.7
296 variant had a 4.484-fold higher risk of having N gene Ct values ≤ 18 in nasopharyngeal
297 swab specimens than the patients infected with non-variant (OR=4.484, $P=0.024$).

298

299 **DISCUSSION**

300 Researches have commonly indicated that the SARS-CoV-2 B.1.1.7 variant had higher
301 transmissibility while whether it had increased pathogenicity remained controversial. In
302 this study, we analyzed the differences of clinical characteristics, laboratory tests, RT-
303 qPCR results and whole-genome features between the 33 cases infected with SARS-
304 CoV-2 B.1.1.7 variant and 41 cases infected with non-variant, and indicated that
305 COVID-19 cases infected with the B.1.1.7 variant had more serious clinical features
306 and possibly higher viral loads. This therefore implies that the B.1.1.7 variant may have
307 increased pathogenicity.

308

309 In the Daxing B.1.1.7 group, we observed an older age of patients than the Shunyi
310 B.1.470 group, probably due to the living characteristics of residents from the

311 community, as many retired older people were more frequently active in the community.

312

313 B.1.1.7 variant infection could lead to a more serious inflammatory response, acute
314 response process and more severe pneumonia as indicated by the following results:
315 compared B.1.1.7 variant cases with non-variant cases, (1) there were more patients
316 with body temperature over 38°C; (2) the laboratory tests of the level of CRP, SAA, CK
317 and DD was significantly higher; (3) the abnormal proportion of CD4⁺T was
318 significantly higher; (4) the patients that had ground glass opacity in the lung were
319 significantly more.

320

321 When comparing the Ct values of the RT-qPCR results between the two groups, samples
322 from the Daxing B.1.1.7 group were related to lower Ct values of N gene, from which
323 it could be speculated that B.1.1.7 variant samples may have a relatively higher viral
324 load. This result corresponded with previous research showing that the B.1.1.7 variant
325 is associated with significantly higher viral loads in samples tested by ThermoFisher
326 TaqPath RT-qPCR¹⁸. Even though the sample size in this study was relatively small, and
327 no significant difference was detected in ORF gene, statistical results for N gene could
328 still somehow indicate a higher infectivity of the B.1.1.7 variant.

329

330 SARS-CoV-2 B.1.1.7 variant infection may be the main risk for more serious clinical
331 features after adjusting the age factor. Old-age has been considered as an important
332 factor in SARS-CoV-2 infection and severe COVID-19, because elderly patients have a

333 weaker immune system function and are prone to multi-system organ dysfunction and
334 even failure¹⁹⁻²². Thus, we adjusted the effect of older age of the Daxing B.1.1.7 group,
335 and still came to the consistent statistically significant results that cases infected with
336 the B.1.1.7 variant presented more serious clinical features and higher infectivity.

337

338 The phylogenetic analysis showed that the strains from the two groups belonged to
339 different lineages. The whole genomic analysis revealed that the case samples from
340 group-DX B.1.1.7 had 3-4 specific substitutions in addition to the 28 nucleotide
341 substitutions corresponding to the B.1.1.7 reference sequence, which indicated that the
342 strains might have been evolving for some time and transmitted to China. The retrieving
343 result of the sequences that had the highest similarity with the strains of the Shunyi
344 B.1.470 group might somehow indicate potential countries of origin. Furthermore, only
345 two amino acid mutations in the S protein were detected in the strains from the Shunyi
346 outbreak, which suggested lower transmissibility compared with B.1.1.7 strains.

347

348 The interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the
349 ACE2 receptor on host cells is vital for viral entry and the N501Y amino acid mutation
350 of B.1.1.7 in RBD of the interface should be favorable for the interaction with
351 ACE2^{14,23,24}. Therefore, N501Y mutation likely increased transmissibility and possibly
352 pathogenicity of B.1.1.7. Other studies indicated that the deletion of 69-70 amino acids
353 on S1 N-terminal domain could enhance virulence and confer resistance to the
354 neutralization antibody of SARS-CoV-2²⁵. Fortunately, many recent studies on the

355 protection of existing vaccines against B.1.1.7 variants all indicated that the B.1.1.7
356 variant will not escape vaccine protection^{14,15,23,24}.

357

358 Nevertheless, currently there is no direct biological experimental evidence that can
359 confirm the increased pathogenicity or virulence of the B.1.1.7 variant and little
360 evaluation of the clinical characteristics of B.1.1.7 variant infection have been
361 conducted. This prospective, comparative cohort study of COVID-19 cases from two
362 COVID-19 outbreaks in Beijing implied that COVID-19 cases led by the B.1.1.7 variant
363 presented more serious clinical and laboratory characteristics than cases infected with
364 non-B.1.1.7 variant (lineage B.1.470).

365

366 Limitations of this study exist. Firstly, due to the very low morbidity of COVID-19 now
367 in China, the sample size in the two groups of this study was relatively small; secondly,
368 we were not able to compare the clinical features of the cases infected with the B.1.1.7
369 variant with the cases infected with other SARS-CoV-2 lineages other than B.1.470.
370 Because during December, 2020 – January 2021, only these two clustered outbreaks had
371 taken place in Beijing, the data of these two groups was more comparable.

372

373 **Contributors**

374 ZC conceived the study; ZC, WX and WZ designed the study; ZC and WZ maintained
375 database for data collection; ZC, WX and WZ supervised the data collection; WZ, SC,
376 ZG, DT, YS, GW, XW, YW, PX, YX, TZ, LL, GL and JT interpreted the data; SC, ZG

377 and GW did the statistical analysis; YS, WZ, SC and ZG wrote the manuscript; YS and
378 SC prepared the figures; YS, XZ, SZ and YW did the COVID-19 specimens processing
379 and sequencing; All authors reviewed and approved the final version of the manuscript.
380 ZC, WZ and WX are the guarantors. The corresponding author attests that all listed
381 authors meet authorship criteria and that no others meeting the criteria have been
382 omitted.

383

384 **Acknowledgments**

385 We thank all physicians who participated in the management of these COVID-19 cases.
386 The study was funded by the National Key Research and Development Program (grant
387 nos. 2020YFC0846200 and 2020YFC0848300) and National Natural Science
388 Foundation of China (grant no. 82072295). The funding body was not involved in the
389 study design, clinical sample collection, data analysis, and interpretation or writing of
390 the manuscript.

391

392 **Declaration of interest**

393 The authors declare that no competing interests exist.

394

395 **Data sharing**

396 The data that support the findings of this study are available from the corresponding
397 author on reasonable request. Participant data without names and identifiers may be
398 shared with other researchers after approval from the corresponding author and the

399 authorities including the Institutional Review Board and the National Health
400 Commission. The proposal with a detailed description of study objectives and a
401 statistical analysis plan will be needed for evaluation of the reasonability to request for
402 our data. The corresponding author will make a decision based on these materials.
403 Following complete publication, the sequence data generated in this study was made
404 available to researchers through GISAID database (accession nos: EPI_ISL_1121993
405 and EPI_ISL_1122015 to 1122017). .

406

407 **Ethical approval**

408 The study was approved by the Institutional Review Board of Beijing Ditan Hospital,
409 Capital Medical University in Beijing (approval number: JDLY2020-020-01).

410

411

412

413 **References**

- 414 1. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected
415 Pneumonia in Wuhan, China. *JAMA* 2020; **323**(11): 1061-9.
- 416 2. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*
417 2020; **382**(8): 727-33.
- 418 3. Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities.
419 *JAMA* 2021.
- 420 4. Tada T, Dcosta BM, Samanovic-Golden M, et al. Neutralization of viruses with European, South African, and United
421 States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. *bioRxiv*
422 2021.
- 423 5. Fujino T, Nomoto H, Kutsuna S, et al. Novel SARS-CoV-2 Variant Identified in Travelers from Brazil to Japan. *Emerg*
424 *Infect Dis* 2021; **27**(4).
- 425 6. Dao MH, Nguyen HT, Nguyen TV, et al. New SARS-CoV-2 Variant of Concern Imported from the United Kingdom to
426 Vietnam, December 2020. *J Med Virol* 2021.
- 427 7. Brookman S, Cook J, Zucherman M, Broughton S, Harman K, Gupta A. Effect of the new SARS-CoV-2 variant B.1.1.7

- 428 on children and young people. *Lancet Child Adolesc Health* 2021.
- 429 8. Mwenda M, Saasa N, Sinyange N, et al. Detection of B.1.351 SARS-CoV-2 Variant Strain - Zambia, December 2020.
430 *MMWR Morb Mortal Wkly Rep* 2021; **70**(8): 280-2.
- 431 9. Rambaut A, Holmes EC, O'Toole A, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
432 epidemiology. *Nat Microbiol* 2020; **5**(11): 1403-7.
- 433 10. Rambaut A, Holmes EC, O'Toole A, et al. Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to
434 assist genomic epidemiology. *Nat Microbiol* 2021; **6**(3): 415.
- 435 11. Alpert T, Lasek-Nesselquist E, Brito AF, et al. Early introductions and community transmission of SARS-CoV-2 variant
436 B.1.1.7 in the United States. *medRxiv* 2021.
- 437 12. Eurosurveillance editorial t. Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-
438 CoV-2 variants of concern in the EU/EEA - first update. *Euro Surveill* 2021; **26**(3).
- 439 13. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of
440 Concern 202012/01 in England. *medRxiv* 2021.
- 441 14. Graham C, Seow J, Huettner I, et al. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing
442 diverse epitopes on SARS-CoV-2 Spike. *bioRxiv* 2021.
- 443 15. Muik A, Wallisch AK, Sanger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-
444 elicited human sera. *Science* 2021.
- 445 16. Peter Horby CH, Nick Davies, John, Edmunds, Neil Ferguson, Graham Medley, Andrew Hayward, Muge Cevik, Calum
446 Semple. NERVTAG note on B.1.1.7 severity. In: SAGE, editor.; 2021.
- 447 17. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill* 2017;
448 **22**(13).
- 449 18. Kidd M, Richter A, Best A, et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads
450 in samples tested by ThermoFisher TaqPath RT-qPCR. *J Infect Dis* 2021.
- 451 19. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-
452 aged patients. *J Infect* 2020; **80**(6): e14-e8.
- 453 20. Han W, Zhu M, Chen J, et al. Lung Transplantation for Elderly Patients With End-Stage COVID-19 Pneumonia. *Ann*
454 *Surg* 2020; **272**(1): e33-e4.
- 455 21. Armitage R, Nellums LB. COVID-19 and the consequences of isolating the elderly. *Lancet Public Health* 2020; **5**(5):
456 e256.
- 457 22. Petretto DR, Pili R. Ageing and COVID-19: What is the Role for Elderly People? *Geriatrics (Basel)* 2020; **5**(2).
- 458 23. Firestone MJ, Lorentz AJ, Wang X, et al. First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota - December
459 2020-January 2021. *MMWR Morb Mortal Wkly Rep* 2021; **70**(8): 278-9.
- 460 24. Edara VV, Floyd K, Lai L, et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant.
461 *medRxiv* 2021.
- 462 25. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2
463 vaccine-elicited sera. *Nat Med* 2021.

464

465

466

467

468 **Tables**

469 **Table 1.** Comparison of the whole-genome features between the two groups

Features	Daxing B.1.1.7 group	Shunyi B.1.470 group
No. of sequences	7	2
PANGO lineage	B.1.1.7	B.1.470
VOC or not	VOC-202012/01	non-VOC
No. of shared nucleotide substitutions	31	24
Shared nucleotide substitution sites (ref. Wuhan-Hu-1, EPI_ISL_402119)	C241T, C913T, C3037T, C3267T, C5388A, C5986T, T6954C, C12036G, C12747T, C12970T, C14408T, C14676T, C15279T, T16176C, A23063T, C23271A, A23403G, C23604A, C23709T, T24506G, G24914C, C27972T, G28048T, A28111G, G28280C, A28281T, T28282A, G28881A, G28882A, G28883C, C28977T	C241T, C1454G, C3037T, T6778C, C9679T, G11291A, T11296G, C14120T, C14408T, C17421T, G18315A, C18687T, C18877T, C21597T, A23403G, G25563T, G25855C, G26051T, C26681T, C26735T, G27870T, C27903T, C28887T, C29311T
Additional substitution site	T21991G	T20246G
Amino acid mutations on Spike protein	H69-V70del, Y144del N501Y, A570D, D614G, P681H, T716I, S982A, D1118H	S12F, D614G

470
471
472
473
474
475
476
477
478
479
480
481

482

Table 2. Comparison of the general situation and clinical manifestations between the

483

two groups

Variable	Daxing B.1.1.7 group (n = 33)	Shunyi B.1.470 group (n = 41)	P value
Male [n, (%)]	15 (45.50)	25 (61.00)	0.183
Age	39.00 (30.50, 62.50)	31.00 (27.50, 41.00)	0.014
Days from onset to admission	1.00 (1.00, 2.00)	1.00 (1.00, 3.00)	0.133
Body Mass Index	23.11 (20.84, 25.08)	22.48 (20.45, 25.57)	0.898
Clinical severity level [n, (%)]			
Asymptomatic	4(12.12)	8 (19.51)	0.391
Mild	7 (21.21)	13 (31.70)	0.312
Moderate	22 (66.67)	20 (48.78)	0.123
Severe	0 (0.00)	0 (0.00)	-
Critical	0 (0.00)	0 (0.00)	-
Underlying disease [n, (%)]	13 (39.39)	14 (34.15)	0.641
Hypertension	3 (9.09)	6 (14.63)	0.723
Diabetes	2 (6.06)	3 (7.32)	> 0.999
Clinical manifestations [n, (%)]			
Fever	19 (57.58)	19 (46.34)	0.337
Temperature $\geq 38^{\circ}\text{C}$	14 (46.43)	9 (21.95)	0.015
Intolerance of cold	2 (6.06)	0 (0.00)	0.195
Dry cough	14 (42.42)	17 (41.46)	0.934
Expectoration	5 (15.15)	4 (9.76)	0.361
Nasal congestion	4 (12.12)	2 (4.88)	0.397
Runny nose	1 (3.03)	2 (4.88)	> 0.999
Hyposmia	1 (3.03)	1 (2.44)	> 0.999
Hypogeusia	0 (0.00)	1 (2.44)	> 0.999
Dry throat/pharyngeal discomfort	6 (18.18)	16 (39.02)	0.051
Sore throat	4 (12.12)	3 (7.32)	0.693
Headache	1 (3.03)	3 (7.32)	0.624
Asthenia	5 (15.15)	1 (2.44)	0.083
Dizziness	2 (6.06)	0 (0.00)	0.195
Muscle soreness	3 (9.09)	3 (7.32)	> 0.999
Joint pain	1 (3.03)	0 (0.00)	0.446
Shortness of breath	0 (0.00)	0 (0.00)	> 0.999
Dyspnea	0 (0.00)	0 (0.00)	> 0.999
Chest tightness	2 (6.06)	2 (4.88)	> 0.999
Chest pain	0 (0.00)	0 (0.00)	> 0.999
Conjunctival hyperemia	0 (0.00)	0 (0.00)	> 0.999
Nausea	0 (0.00)	2 (4.88)	0.499
Vomiting	0 (0.00)	0 (0.00)	> 0.999
Diarrhea	1 (3.03)	2 (4.88)	> 0.999

Abdominal pain 0 (0.00) 0 (0.00) > 0.999

484

485

486

Table 3. Comparison of laboratory tests, CT results and treatment measures

Variable	Daxing B.1.1.7 group (n = 33)	Shunyi B.1.470 group (n = 41)	P value
Laboratory tests			
White blood cell count($\times 10^9/L$)	5.16 (4.32, 7.15)	5.69 (4.49, 7.02)	0.628
Neutrophil count ($\times 10^9/L$)	3.23 (2.60, 4.55)	3.45 (2.44, 4.64)	0.948
Neutrophil percentage (%)	65.30 (54.42, 71.25)	62.30 (56.90, 72.96)	0.786
Lymphocyte count ($\times 10^9/L$)	1.42 (0.93, 1.91)	1.39 (0.91, 1.82)	0.996
Lymphocyte percentage (%)	23.44 (19.25, 34.25)	27.40 (18.02, 35.05)	0.732
Platelet count($\times 10^9/L$)	223.00 (185.00, 262.50)	217.40 (181.50, 269.00)	0.716
C-reactive protein (mg/L)	4.30 (2.45, 12.15)	1.80, (0.85, 4.95)	0.005
Serum amyloid A (mg/L)	21.50 (12.50, 50.70)	12.00 (5.20, 26.95)	0.003
Alanine aminotransferase (U/L)	16.60 (11.15, 28.50)	21.00 (12.55, 37.80)	0.370
Aspartate aminotransferase (U/L)	26.30 (18.90, 34.15)	23.20 (17.85, 29.45)	0.236
Lactic Dehydrogenase (U/L)	187.50 (170.05, 228.15)	194.90 (174.25,224.80)	0.708
Creatine Kinase (U/L)	110.50 (53.15,152.40)	70.40 (54.35,103.05)	0.040
Prothrombin Time (s)	12.20 (11.60,12.70)	12.20 (11.45,12.80)	0.947
Activated partial thromboplastin Time (s)	33.50 (30.80,35.10)	31.75 (29.50,34.35)	0.257
D-dimer (mg/L)	0.31 (0.20, 0.48)	0.24 (0.17, 0.31)	0.038
T lymphocyte (cells/uL)			
<1027	14.00 (43.75)	21.00 (53.85)	0.397
≥ 1027	18.00 (56.25)	18.00 (46.15)	
CD4 ⁺ T lymphocyte (cells/uL)			0.003
<706	21.00 (65.63)	12.00 (30.77)	
≥ 706	11.00 (34.38)	27.00 (69.23)	
CD8 ⁺ T lymphocyte (cells/uL)			
<320	15.00 (46.88)	17.00 (43.60)	0.782
≥ 320	17.00 (53.13)	22.00 (56.41)	
Imaging examination [n, (%)]			
Pneumonia unilateral	10.00 (30.30)	15.00 (36.59)	0.570
Pneumonia	15.00 (45.45)	11.00 (26.83)	0.095
Ground glass opacity	15.00 (45.45)	5.00 (12.20)	0.001
Antibody detection [n, (%)]			
IgM (+)	1.00 (3.03)	2.00 (4.88)	> 0.999
IgG (+)	1.00 (3.03)	3.00 (7.32)	> 0.999
Treatments [n, (%)]			
Favelavir	7.00 (21.21)	4.00 (9.76)	0.295

Favelavir + Abidol	1.00 (3.03)	4.00 (9.76)	0.373
Interferon	1.00 (3.03)	1.00 (2.44)	> 0.999
Traditional Chinese medicine	23.00 (69.70)	27.00 (65.85)	0.726
Oxygen inhalation	5.00 (15.15)	8.00 (19.51)	0.624

487

488

489 **Table 4.** Risk of CRP, SAA and GGO of patients upon variant (B.1.1.7 variant

490 infection or non-variant infection)

Outcomes	Variables	Regression coefficient	Standard error	Wald Chisq Value	P value	Odds ratio	95% CI for OR
Level of CRP (<7mg/L or ≥7 mg/L)	Age	0.00	0.01	0.03	0.854	1.00	[0.98, 1.03]
	Group	1.09	0.54	4.02	0.045	2.79	[1.03, 0.86]
Level of SAA (<10mg/L or ≥10 mg/L)	Age	0.03	0.02	2.63	0.105	1.03	[0.99, 1.06]
	Group	1.62	0.63	6.54	0.011	5.03	[1.45, 17.35]
Had GGO or not	Age	0.01	0.02	0.69	0.408	1.01	[0.98, 1.04]
	Group	1.69	0.61	7.80	0.005	5.42	[1.66, 17.73]
Level of CK (<150U/L or ≥150U/L)	Age	0.00	0.02	0.05	0.821	1.00	[0.97, 1.04]
	Group	-1.52	0.73	4.34	0.034	0.22	[0.05, 0.91]
Level of DD (<0.5mg/L or ≥0.5mg/L)	Age	0.06	0.03	6.14	0.013	1.07	[1.01, 1.12]
	Group	0.70	0.82	0.73	0.392	2.01	[0.41, 10.02]
Level of CD4 ⁺ T (<706cells/uL or ≥706cells/uL)	Age	0.05	0.02	7.55	0.006	1.05	[1.01, 1.08]
	Group	1.20	0.55	4.77	0.029	3.31	[1.13, 9.71]

491

492 **Table 5.** Compared lowest RT-qPCR Ct values in two groups

Lowest Ct values	Daxing B.1.1.7 group (n=33)	Shunyi B.1.470 group (n=41)	P value
ORF1ab (Mean ± SD*)	23.33 ± 4.24	24.31 ± 5.21	0.417
N (Mean ± SD)	20.58 ± 4.34	23.22 ± 5.37	0.036

493 *SD, Standard Deviation

494

495

496 **Table 6.** Risk of Ct values of N gene-target of patients upon variant (B.1.1.7
497 variant infection or non-variant infection)
498

Variables	Regression coefficient	Standard error	Wald Chisq Value	P value	Odds ratio	95% CI for OR
Age	-0.01	0.02	0.42	0.518	0.99	[0.96, 1.02]
Group	1.50	0.67	5.08	0.024	4.48	[1.22, 16.53]

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520


521

524

525 **Figure 1.** Neighbor-Joining phylogenetic tree based on the whole genome sequences of
526 the SARS-CoV-2 representative strains. The two representative strains from the Daxing
527 B.1.1.7 group were indicated by deep blue dots, font and a left arrow; while the strains
528 from the Shunyi B.1.470 group were indicated by red dots, font and a left arrow. Strains
529 associated with other previous outbreaks in China were indicated with ice blue triangles.
530 The B.1.1.7 and B.1.470 lineage was highlighted with blue and light red background,
531 respectively, the two strains that shared high homology with the strains of the Shunyi
532 B.1.470 group were colored in purple font. The Wuhan reference strain was shaded in
533 gray. The PANGO lineages were marked and colored on the right. The tree was rooted
534 using strain WH04 (EPI_ISL_406801) in accord with the root of Pangolin tree.

535

536



537

538

539 **Figure 2.** Scatter plot of the RT-qPCR Ct values of the Daxing B.1.1.7 group and the
540 Shunyi B.1.470 group. (A) Ct values of ORF1ab-gene target; (B) Ct values of N-gene
541 target. Samples from the Daxing B.1.1.7 group were shown as red dots while from the
542 Shunyi B.1.470 group as blue dots. Median Ct was indicated by a black horizon bar.